Thanks, thank start. joining pleased I'm today. a that you off tell Doug. you and us to XXXX strong for is afternoon Good to
XX% first geographies and This core our the business in segments. across nCounter customer revenue. biopharma During and product in service included drove growth quarter, double-digit academic solid growth all both
our the call the year. of the begin a turning over setting addition, before driver customer I'll to In strategic to operating interest with for first of results in quarter. objectives Tom review spatial on profiler new our growth up this XXXX second our to build, an digital the for details continues for genomics the update half call
sustain XXXX in consumable pull revenue, base. our our our for objective through strong double-digit business. will expanding core into which be we call, nCounter by March is on first expected is leverage primarily growth This As to steadily growth driven strategic our outlined install to
as diagnostics. In prior the an life per all-time over $XX,XXX year. offset growing year-on-year. set $XX,XXX was from through in $XX.X of XX% of in an slower system, revenue record, Annualized Our half sciences increase the of to of was strength in the first revenue pull total in range products QX excess top XX% Panel quarter, million, growth consumable consumable guided our from
immuno-oncology the during (NYSE:IO) Set quarter. grew both PanCancer Code quarter. a with were Our panels sales which our record Profiling legacy our highlight, during the also Immune were and the Panel as We Panel achieved XXX our performance pleased Custom business,
Panel to accounts, continue which We XX% grew and and non-oncology year-on-year. penetrate neurology, revenue like immunology
track of the our achieved over XXXX. made we we improvements our panels launch to has our on force bandwidth Demand with year consistent full sales of be and sales envisioned, the to instrument The instrument healthy addressing metabolic the last and exactly to accelerating on pathways as of fibrosis. dividends. focus providing continue we managers year to new consumables, The for our regional what remain several over Systems including remains for additional nCounter revenue bifurcation expect and pay balance in our important funnel. with have addition, topics In the research year, such channel
oncology of customers studies, data the instrument the DSP high continued year replacements to the Oncology as During first with base nCounter. and including our MAX XX AACR strong accounted balance XX% result neurology. we presented install as where were of level approximately our activity applications demonstrates our throughput systems, XX% demand of our systems, XXX of the nCounter companies, was putting it sales in the QX, approximately part Systems from instrument in of nCounter of systems, recent GeoMx The immunology new from and impact to install biopharma approximately expanded a above The from bundles. base quarter going at ago. for over our majority meeting
During AACR, the manufacturing will in characterization, Panel, CAR-T find we of we and believe our had dialogue utility on development, which focused cellular customer substantial therapies.
appeal assay, the study LymphMark On in approval the significant versus in last Study, endpoint standard patients a a in was announced was diagnostic do of DLBCL as LymphMark side, North Prosigna but Celgene provide of is as lenalidomide month, its that clinical that medical the primary QX, of not care. survival for value support some standard Late of Phase Patient where III patients market evaluating enrollment of guidelines. accounts. DLBCL remains in Europe the origin, competitive of America cell based XXXX using away subtyping Performance strongest. can lymphoma results for for of That us progression ROBUST believe on to not testing there said, as decentralized classification free regulatory disease. the revenue we did being the solid this companion trial saw a achieve addition weaker share growth counter-detailing conducted unmet WHO per study need that subgroup And during of in care shifted in our indication. improved the diagnostic for a selection seeking LymphMark this from
the to path test companies who for pilot origin run approximately studies XX assay for a independently of LymphMark commercial the explore as subtyping cell stratification. and/or in continue with one have different patient partnership We a using of biopharma
spatial for success. the GeoMx our on objective profiler year for is Our digital to trajectory launch a strategic long-term second
we development projects expectations ago technology introduction Our provides access completed prototype which more of two years diverse for consistently instruments. efforts XX TAP, have Demand began with based of a on XX set TAP than now market than than more service our our for customers. GeoMx the or exceeded program, and more for has
to complete formats, for biomarkers, we These use invaluable anticipate input into and biology. insights us solution interactions, and real-time who preferred address efforts, design, allowing likely deliver researchers to techniques. spatial are hunting cancer for DSP, provided product a how to During are needs researchers gained have insights these for analytical consumable our the including development experimental and of integrated
throughput other former that sensor provides to content, and a this and GeoMx of larger mitt, intuitive GeoMx consumable a companies high partnerships software, powerful leading ecosystem. solution visualization validated In the addition suite with
Our during launch place at last generated new AACR Cancer Association is the on about interest Research leads X,XXX focused times booth leads full GeoMx AACR, year. of of for prior with total, took more We X driven commercial which as and month, than customer traffic. XX% customer many at that we customer the record generating In by Conference balance estimate nCounter. GeoMx American as dialogue the the was
for fixed enabled spanning include tissue protein selection, on unveiled At high-end DSP our menu panel pricing launches interest we modular expanding supporting and portfolio of design. protein $XXX,XXX, key immuno-oncology readout XX profiles used any This in more be the customers RNA XXX throughout GeoMx priced for The are will GeoMx. RNA panels pathology. tailor panels GeoMx kits GeoMx will scanners allows immuno-oncology. consumable targets neuroscience a their AACR, experimental validated our protein instrument than During all consumable widely which that over for contents at XX X consumable of launch, regions targets, of and platforms. of and with comparable to The morphology assays nCounter initial and to modular time. slide strategy initially research and format is
regions more affordable targeted panels more sample choose comprehensive markers For by or interest. per instance, price of adding more at up can content or a customers highly to entry buy
be our researchers for is price We twice revenue expect than nCounter per per sample, the sample average $XXX translational per spend customers to the about on which average about sample current panels.
for directly interface AACR, GeoMx a which to also map expression biomarkers, intuitive novel and provides an software, showcased of signatures, During spatial discovery context, translational opening era gene our we profiles to the research. new
were add software were platform visualize, our the tumor the the segmenting all versus toolkit and deep forth capabilities impressed to separate and compartments demonstrations high-resolution drew the molecular software biological by molecular leave GeoMx the creating early customers booth. Customers samples available images platform for the only phenotype, and Other themselves. of microenvironment. software that and post-launch launch, captivated steady launches profiles contrasts stream particular interested of fend tissue browse seeing with on by the Our back tissue the completeness analyze, Many in cell of between a solution were AACR at capabilities the profiling to interest for other which based and customers screen. to same on researchers, for the ability of often
us several designed Finally, announce around excellent partnerships and for venue capabilities to and build an ecosystem AACR GeoMx, automating its content, provided an to expanding its workflow.
high of at across RNA popular assays sensitivity. slide first is on combines enable set will the with RNA content unique or cell with workflow NanoString the a of kits, Our business Bio-Techne. ACD's ACD Bio-Techne and co-promote advanced visualization an entire targets RNA that GeoMx the scope and that our RNA front a diagnostics, assays with partnership
as demonstrated We guide on a have scope workflow morphology of GeoMx. to utilizes profiling interest already molecular of the of RNA selections regions feasibility reagents for that the deep kits
During a we the AACR, program. customers. the and paper NanoString announced both of And demonstrated ACD introduced we technology RNAscope access and availability workflow within results immediate that white our capabilities to
CFD, not that and will [indiscernible] very our la of vast the for This a a will on access focuses global drawing its for to library antibodies. leading GeoMx its own. in with approximately Abcam, IHC available expanding FFPE partnership leveraging far-reaching antibodies Abcam user channels. provider rapidly tissue, second from the with Our customers on content on antibodies a convenient protein GeoMx validated distribution provide with X,XXX of carte our easily could provide make partnership antibodies we oligo-conjugated
RX for provide positive. these and instrument, has anticipated systems updates automation and overwhelmingly through the with been Leica of GeoMx. than Customer straining situ to co-market DSP GeoMx and that which were an Bond customers X,XXX their to to provides proactively will Danaher that with tissue this Biosystems promote trust. GeoMx a partnership Bond now website protein of company, working autostainer to software adoption Biosystems reproducible market we're platform. match with encouraged their solution protocols by we've DSP already the a its in worldwide, for who automate and throughput RX and will appreciation reaction great representatives GeoMx, to processing sells addressed way partnerships more to they customers. we've expressed RX Leica protocols its Leica know the to and With GeoMx increase bond partnered a leaders through Bond hybridization, Customers available Finally, DSP making and results RNA immunohistochemistry needs Biosystems, with installed its awareness sales X automates on that customers which and instrument. autostainer the GeoMx
fact to bring scientific companies research of addition at based those that to XX the commercial primarily more interest GeoMx our a DSP field GeoMx launch date including M.D. was throughout and launch customers quarter, These year-end showcased at you from from reported at to continue AACR, studies Vanderbilt, orders Biosciences. DSP, first that HX In biopharma orders tell XX the X during and cancer cumulative pre-launch looking our on and team the XX. Pharmaceuticals preparing like to place total for Anderson customers publications. GeoMx the more we of activities strong orders QX, for scientific preordered we peer like focused centers than review presented number and more as of I'm the GeoMx Janssen Despite number to March than abstracts XX of XX to excited systems instruments. expanded from to we on than studies
previously of book our GeoMx we the consider made of in launches a year. QX, are industrial up in on been no are when launch, order X/X impressive such you biopharma more the of as were preorders XX field. QX customers is favorably flow, attractive We by all To that orders the that launch CROs. the we other are program we especially offered last to which into than and date, that With promotional compares companies site X/X providing and believe during had about priority product elements longer under are customers, heading academic that delighted trajectory
instrument MAX So far, new about through with these throughput system. of being vast pulled high have XX% the of preorders a our our nCounter majority
installing in third begin GeoMx commercial Systems We are our to quarter. beginning track on first the
GeoMx, to expect [indiscernible] The a the platform install our likely launch be we've orders of that are second commercializing to in in the parallel XXXX. to toward to which invest this is continued GeoMx year strategic over in the XX our balance half advance of fulfilled third XXXX. we to in commercial we received of booked XX hide-and-seek this we During to that year, preorders XXXX. objective, In
November, in for focused simultaneously this when platform update efforts next we on requirements, expression the increasing our profiled targets planned hide-and-seek input the a the applications. Conference coming AMP platform During of technical the the refining provide QX, reducing of and use the clinical major for technical is sample of utility expect profiling. number update on gene The to
Tom the the details over quarter like to first results. of to to turn our Now, call I'd review
